Modality
Degrader
MOA
AHRant
Target
CD38
Pathway
PD-1/PD-L1
Ewing SarcomaAS
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
Oct 2018
→ Jul 2031
Phase 3Current
NCT08400523
1,558 pts·AS
2023-08→2030-11·Not yet recruiting
NCT08093731
2,421 pts·Ewing Sarcoma
2020-03→2027-02·Completed
NCT06884893
2,702 pts·Ewing Sarcoma
2018-10→2031-07·Terminated
6,681 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2026-11-208mo awayFast Track· Ewing Sarcoma
2027-02-0510mo awayPh3 Readout· Ewing Sarcoma
2030-11-194.6y awayPh3 Readout· AS
2031-07-265.3y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
P3
Complet…
P3
Not yet…
Catalysts
Fast Track
2026-11-20 · 8mo away
Ewing Sarcoma
Ph3 Readout
2027-02-05 · 10mo away
Ewing Sarcoma
Ph3 Readout
2030-11-19 · 4.6y away
AS
Ph3 Readout
2031-07-26 · 5.3y away
Ewing Sarcoma
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08400523 | Phase 3 | AS | Not yet recr... | 1558 | EDSS |
| NCT08093731 | Phase 3 | Ewing Sarcoma | Completed | 2421 | DAS28 |
| NCT06884893 | Phase 3 | Ewing Sarcoma | Terminated | 2702 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| Ivosotorasib | Vertex Pharma | Preclinical | CD38 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 |